Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_4
1
33%
Ph phase_2
1
33%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_4

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

NCT01333501
completedphase_3

RNF and Betaseron® Tolerability Study

NCT00428584
completedphase_2

Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b

NCT00942591

Clinical Trials (3)

Showing 3 of 3 trials
NCT01333501Phase 4

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Completed
NCT00428584Phase 3

RNF and Betaseron® Tolerability Study

Completed
NCT00942591Phase 2

Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3